Decoy Therapeutics Inc. Comprehensive Income
Decoy Therapeutics Inc. (DCOY) reported Comprehensive Income of -$1.38 million for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-07-17.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2019-07-17
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-06-30 was -$1.38M.
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2019-03-31 was -$2.23M.
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-12-31 was -$2.01M.
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-09-30 was -$2.64M.
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$21.92M.
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$34.43M.
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$39.47M.
- Decoy Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2015 was -$29.17M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 4 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 7 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 10 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|---|---|
| 2019-06-30 | -$1.38M 10-Q · filed 2019-07-17 | -$3.62M 10-Q · filed 2019-07-17 | -$5.62M derived: sum of 3 quarters · filed 2019-07-17 | -$8.26M derived: sum of 4 quarters · filed 2019-07-17 | ||||
| 2019-03-31 | -$2.23M 10-Q · filed 2019-05-01 | -$4.24M derived: sum of 2 quarters · filed 2019-05-01 | -$6.88M derived: sum of 3 quarters · filed 2019-05-01 | -$15.93M derived: sum of 4 quarters · filed 2019-07-17 | ||||
| 2018-12-31 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$4.65M derived: sum of 2 quarters · filed 2019-03-06 | -$13.70M derived: sum of 3 quarters · filed 2019-07-17 | -$21.92M 10-K · filed 2019-03-06 | ||||
| 2018-09-30 | -$2.64M 10-Q · filed 2018-11-05 | -$11.69M derived: sum of 2 quarters · filed 2019-07-17 | -$19.91M 10-Q · filed 2018-11-05 | -$27.94M derived: sum of 4 quarters · filed 2019-07-17 | ||||
| 2018-06-30 | -$9.05M 10-Q · filed 2019-07-17 | -$17.27M 10-Q · filed 2019-07-17 | -$25.30M derived: sum of 3 quarters · filed 2019-07-17 | -$34.63M derived: sum of 4 quarters · filed 2019-07-17 | ||||
| 2018-03-31 | -$8.22M 10-Q · filed 2019-05-01 | -$16.25M derived: sum of 2 quarters · filed 2019-05-01 | -$25.58M derived: sum of 3 quarters · filed 2019-05-01 | -$34.38M derived: sum of 4 quarters · filed 2019-05-01 | ||||
| 2017-12-31 | -$8.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$17.36M derived: sum of 2 quarters · filed 2019-03-06 | -$26.15M derived: sum of 3 quarters · filed 2019-03-06 | -$34.43M 10-K · filed 2019-03-06 | ||||
| 2017-09-30 | -$9.33M 10-Q · filed 2018-11-05 | -$18.13M derived: sum of 2 quarters · filed 2018-11-05 | -$26.40M 10-Q · filed 2018-11-05 | -$34.32M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2017-06-30 | -$8.80M 10-Q · filed 2018-08-01 | -$17.08M 10-Q · filed 2018-08-01 | -$24.99M derived: sum of 3 quarters · filed 2019-03-06 | -$35.66M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2017-03-31 | -$8.28M 10-Q · filed 2018-05-02 | -$16.20M derived: sum of 2 quarters · filed 2019-03-06 | -$26.86M derived: sum of 3 quarters · filed 2019-03-06 | -$38.20M derived: sum of 4 quarters · filed 2019-03-06 | ||||
| 2016-12-31 | -$7.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | -$18.58M derived: sum of 2 quarters · filed 2019-03-06 | -$29.92M derived: sum of 3 quarters · filed 2019-03-06 | -$39.47M 10-K · filed 2019-03-06 | ||||
| 2016-09-30 | -$10.66M 10-Q · filed 2017-11-06 | -$22.01M derived: sum of 2 quarters · filed 2017-11-06 | -$31.55M 10-Q · filed 2017-11-06 | -$39.47M derived: sum of 4 quarters · filed 2018-03-07 | ||||
| 2016-06-30 | -$11.34M 10-Q · filed 2017-08-02 | -$20.89M 10-Q · filed 2017-08-02 | -$28.81M derived: sum of 3 quarters · filed 2018-03-07 | -$36.96M derived: sum of 4 quarters · filed 2018-03-07 | ||||
| 2016-03-31 | -$9.55M 10-Q · filed 2017-05-03 | -$17.46M derived: sum of 2 quarters · filed 2018-03-07 | -$25.62M derived: sum of 3 quarters · filed 2018-03-07 | -$32.70M derived: sum of 4 quarters · filed 2018-03-07 | ||||
| 2015-12-31 | -$7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$16.07M derived: sum of 2 quarters · filed 2018-03-07 | -$23.15M derived: sum of 3 quarters · filed 2018-03-07 | -$29.17M 10-K · filed 2018-03-07 | ||||
| 2015-09-30 | -$8.16M 10-Q · filed 2016-11-02 | -$15.23M derived: sum of 2 quarters · filed 2016-11-02 | -$21.25M 10-Q · filed 2016-11-02 | |||||
| 2015-06-30 | -$7.08M 10-Q · filed 2016-08-03 | -$13.10M 10-Q · filed 2016-08-03 | ||||||
| 2015-03-31 | -$6.02M 10-Q · filed 2016-05-04 | |||||||
| 2014-12-31 | -$8.01M 10-K · filed 2017-03-08 | |||||||
| 2014-09-30 | -$1.99M 10-Q · filed 2015-11-04 | -$4.18M derived: sum of 2 quarters · filed 2015-11-04 | -$4.27M 10-Q · filed 2015-11-04 | |||||
| 2014-06-30 | -$2.19M 10-Q · filed 2015-08-05 | -$2.28M 10-Q · filed 2015-08-05 | ||||||
| 2014-03-31 | -$92.72K 10-Q · filed 2015-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |